Study: Major Drop in Vaping by Under-20s During 2020

Market by Vapor Voice
Jul.25.2022

Use of e-cigarettes vaping devices dropped during the first year of the Covid-19 pandemic, according to a new study.

Study: Major Drop in Vaping by Under-20s During 2020

Researchers from Johns Hopkins University in Baltimore, Maryland, found that usage of vaping products dropped seven percent overall from 2018 to 2020 – including a 17 percent drop among people aged 18 to 20.

 

Researchers published their findings Friday on the JAMA Network Open after gathering data from the U.S. Centers for Disease Control (CDC) and Prevention’s Behavioral Risk Factor Surveillance System for the study, according to media reports.

 

The survey included a total of 994,307 respondents. In 2017, the CDC reported 4.4 percent of U.S. adults reported use of an e-cigarette. The figure climbed 25 percent to 5.5 percent in 2018.

 

‘This increase, primarily observed in younger age groups, was associated with the concurrent rise in the availability of flavored products and high nicotine–concentration pod mod devices (modular vaping devices with refillable or replaceable nicotine cartridges, or pods, such as JUUL brand devices),’ the researcher’s wrote in the study.

 

Data from 2019 was not gathered. In 2020, overall usage of e-cigarettes fell to 5.1 percent, a seven percent drop from two years earlier. The most dramatic shift was seen among people aged 18 to 20 years old – the youngest group included in the study.

 

The content excerpted or reproduced in this article comes from a third-party, and the copyright belongs to the original media and author. If any infringement is found, please contact us to delete it. Any entity or individual wishing to forward the information, please contact the author and refrain from forwarding directly from here.

U.S. FDA Includes Cytisinicline for Vaping Addiction in National Priority Voucher Program, Shortens Review to 1–2 Months
U.S. FDA Includes Cytisinicline for Vaping Addiction in National Priority Voucher Program, Shortens Review to 1–2 Months
The U.S. Food and Drug Administration (FDA) has added Cytisinicline, a plant-based therapy developed by Achieve Life Sciences for nicotine vaping addiction, to its new National Priority Voucher (CNPV) program. The initiative shortens drug review timelines from 10–12 months to just 1–2 months, expediting approval for treatments that address major public health needs.
Oct.20 by 2FIRSTS.ai
1,200 Health Leaders Urge UK Parliament to Pass Tobacco and Vapes Bill Swiftly
1,200 Health Leaders Urge UK Parliament to Pass Tobacco and Vapes Bill Swiftly
Over 1,200 UK health leaders urged Parliament to pass the Tobacco and Vapes Bill quickly, calling it vital to protect future generations. The bill would ban tobacco sales to anyone born after Jan 1, 2009, and restrict vape packaging and flavours. Health groups warned delays risk undermining “gamechanging” public health reforms.
Oct.27 by 2FIRSTS.ai
KT&G Unveils lil hybrid 3.0 Misty Rose Limited Edition, Limited to 20,000 Devices
KT&G Unveils lil hybrid 3.0 Misty Rose Limited Edition, Limited to 20,000 Devices
KT&G has launched the limited-edition “lil hybrid 3.0 Misty Rose Edition” heated tobacco device in South Korea, betting on year-end consumer demand with a gradient rose-colored design. The release is capped at 20,000 units and is available through both online and offline channels, with an official retail price of 78,000 won (approximately USD 53).
Nov.20 by 2FIRSTS.ai
ceshi
ceshi
Nov.04
Malaysia Collected US$50.07 million in Vape Tax Since April 2023
Malaysia Collected US$50.07 million in Vape Tax Since April 2023
Malaysia collected RM209.5 million(US$50.07 million) in excise duty on nicotine-containing vape liquids and gels from April 2023 to August 2025, according to Finance Ministry data. However, Health Minister Dr Dzulkefly Ahmad said RM223.5 million was spent treating EVALI patients in the past year alone, exceeding the tax revenue.
Nov.06 by 2FIRSTS.ai
ARAC to 2Firsts | FDA’s Nicotine Pouch Pilot: What Hasn’t Changed Matters Most
ARAC to 2Firsts | FDA’s Nicotine Pouch Pilot: What Hasn’t Changed Matters Most
In a contribution to 2Firsts, U.S. regulatory consultancy ARAC analyzes the FDA’s nicotine pouch PMTA pilot, cautioning that core evidentiary standards remain unchanged. The firm warns against overinterpreting the pilot and urges companies to act now rather than wait for uncertain regulatory shifts.
Oct.21